The short version of Nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
== Limitations == Although well ordered nanostructures have already been successfully formed from self-assembling peptides, their potential will not be fully fulfilled until useful functionality is incorporated into the structures. Moreover, so far most of the peptide structures formed are in one or two dimensions. In contrast, in nature, most biological structures are in three dimensions. Criticism has come because there is a lack of theoretical knowledge about the self-assembling behaviours of peptides. Further knowledge could prove to be very useful in facilitating rational designs and precise control of the peptide assemblies. Lastly, although an extensive amount of work is being conducted on developing self-assembling peptide-related applications, issues such as commercial viability and processability have not been paid the same amount of attention. Yet these issues must be assessed if further useful applications are to be realized.
Most proteins fold into unique 3D structures. The shape into which a protein naturally folds is known as its native conformation. Although many proteins can fold unassisted, simply through the chemical properties of their amino acids, others require the aid of molecular chaperones to fold into their native states. Biochemists often refer to four distinct aspects of a protein's structure:
In 2015, in the Journal of Molluscan Studies, Puillandre, Duda, Meyer, Olivera & Bouchet presented a new classification for the old genus Conus. Using 329 species, the authors carried out molecular phylogenetic analyses. The results suggested that the authors should place all cone snails in a single family, Conidae, containing four genera: Conus, Conasprella, Profundiconus and Californiconus. The authors group 85% of all known cone snail species under Conus. They recognize 57 subgenera within Conus, and 11 subgenera within the genus Conasprella.
For example, the Archbishop of Reggio Calabria, Carmelo Pujia, an interventionist on the eve of World War, had a prayer composed praising the glory of the homeland and the Italian flag. Under the Fascist regime, concentration camps were built in Calabria and used to imprison foreigners whose presence was considered undesirable, such as Chinese immigrants and foreign (though not Italian) Jews together with members of the Romani minority, whose nomadic lifestyle was viewed as anti-social. The camps operated from 1938 to 1943. They were harsh, butt not death camps, (the majority of those imprisoned survived).
=== Oral GLP-1 Semaglutide Generic === SCD has been developing an oral generic version of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. In January 2026, SCD signed a partnership agreement with Daiichi Sankyo Espha, a subsidiary of Japan's Daiichi Sankyo, for the exclusive sale of oral semaglutide generics in Japan. Some industry observers and analysts have questioned the company's public statements regarding this product. A commentary published by the Korea Biomedical Review in July 2025 noted that SCD's claims of a potential 2026 market launch for its oral semaglutide generic appeared to overstate the company's regulatory position, given that secondary patents on semaglutide formulations are widely expected to remain in force until at least 2031 in most major markets.
Sources: en.wikipedia.org
== Modern definitions == In broad metaphorical (colloquial) usage of the term, "poison" may refer to anything deemed harmful. In biology, poisons are substances that can cause death, injury, or harm to organs, tissues, cells, and DNA usually by chemical reactions or other activity on the molecular scale, when an organism is exposed to a sufficient quantity. Medicinal fields (particularly veterinary medicine) and zoology often distinguish poisons from toxins and venoms. Both poisons and venoms are toxins, which are toxicants produced by organisms in nature. The difference between venom and poison is the delivery method of the toxin. Venoms are toxins that are actively delivered by being injected via a bite or sting through a venom apparatus, such as fangs or a stinger, in a process called envenomation, whereas poisons are toxins that are passively delivered by being swallowed, inhaled, or absorbed through the skin. Unantidoteable refers to toxins that cannot be neutralized by modern medical technology, regardless of their type.
Moscow will gain a branch of the Hermitage Museum in 2024. Authorities have agreed on the final project, which will be executed by Hani Rashid, co-founder of the New York-based firm Asymptote Architecture. This firm handled the stock market building in Moscow, the World Business Center Solomon Tower in Busan, and the Strata Tower in Abu Dhabi.
CoA-glutathione + glutathione Thus, the two substrates of this enzyme are CoA and glutathione disulfide, whereas its two products are CoA-glutathione and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is CoA:glutathione-disulfide oxidoreductase. Other names in common use include glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione coenzyme A-glutathione transhydrogenase, glutathione:coenzyme A-glutathione transhydrogenase, coenzyme A:oxidized-glutathione oxidoreductase, and coenzyme A:glutathione-disulfide oxidoreductase. This enzyme participates in cysteine metabolism and glutathione metabolism.
==== MeSH E05.393.525 – molecular probe techniques ==== MeSH E05.393.525.085 – biotinylation MeSH E05.393.525.100 – blotting, northern MeSH E05.393.525.150 – blotting, southern MeSH E05.393.525.225 – blotting, southwestern MeSH E05.393.525.300 – branched dna signal amplification assay MeSH E05.393.525.640 – oligonucleotide array sequence analysis MeSH E05.393.525.680 – protein array analysis MeSH E05.393.525.700 – random amplified polymorphic dna technique MeSH E05.393.525.870 – two-hybrid system techniques
=== Reactivity at carbon (C-3 and C-6) === Regio- and stereocontrolled C-functionalization of 2,5-diketopiperazines at C-3 and C-6 involve enolate, radical and cationic precursors (and N-acyliminium ion) and are sensitive to polar and steric effects.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.